ReviewPharmacoEconomics2017
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
Ros Wade et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ReviewPharmacoEconomics2017
Ros Wade et al.PubMed ↗Publisher ↗
No numbers read from the abstract.